Quick Takeaways
- Jennifer Jarrett has 8 issuer positions tracked on this page.
- Estimated disclosed ownership value: $19,348,954.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Jennifer Jarrett
- Location
- San Francisco, CA
- Summary
- The estimated net worth of Jennifer Jarrett is at least $19,348,954 dollars as of 01 Apr 2026. Jennifer Jarrett is the President and Chief Executive Officer, Director of Damora Therapeutics, Inc. and owns shares of Damora Therapeutics, Inc. (DMRA) stock worth about $11.5M. Jennifer Jarrett is the Chief Operating Officer of Arcus Biosciences, Inc. and owns shares of Arcus Biosciences, Inc. (RCUS) stock worth about $5.44M. Jennifer Jarrett is the Director of Syndax Pharmaceuticals Inc and owns shares of Syndax Pharmaceuticals Inc (SNDX) stock worth about $2.4M. Jennifer Jarrett is the Former Director of Surrozen, Inc./DE and owns shares of Surrozen, Inc./DE (SRZN) stock worth about $11.4K.
- Signature
- /s/ Garrett Winslow, attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Jennifer Jarrett and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Damora Therapeutics, Inc. ($11,505,000).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Jennifer Jarrett
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | President and Chief Executive Officer, Director | $11,505,000 | 30 Mar 2026 | ||
| RCUS | Arcus Biosciences, Inc. | Chief Operating Officer | $5,437,414 | -$2,171,347 | -29% | 23 Jan 2026 |
| SNDX | Syndax Pharmaceuticals Inc | Director | $2,395,140 | 04 Feb 2026 | ||
| SRZN, SRZNW | Surrozen, Inc./DE | Former Director | $11,400 | 11 Aug 2021 | ||
| ARNA | ARENA PHARMACEUTICALS INC | Director | 11 Mar 2022 | |||
| RDUS | Radius Health, Inc. | Director | 15 Aug 2022 | |||
| SGMT | Sagimet Biosciences Inc. | Director | 09 Jun 2025 | |||
| ZURA | Zura Bio Ltd | Director | 21 May 2025 |
Insider Transactions Reported by Jennifer Jarrett:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.